Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
22
02
2024
accepted:
31
05
2024
revised:
29
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Measurable residual disease (MRD) surveillance in acute myeloid leukemia (AML) may identify patients destined for relapse and thus provide the option of pre-emptive therapy to improve their outcome. Whilst flow cytometric MRD (Flow-MRD) can be applied to high-risk AML/ myelodysplasia patients, its diagnostic performance for detecting impending relapse is unknown. We evaluated this in a cohort comprising 136 true positives (bone marrows preceding relapse by a median of 2.45 months) and 155 true negatives (bone marrows during sustained remission). At an optimal Flow-MRD threshold of 0.040%, clinical sensitivity and specificity for relapse was 74% and 87% respectively (51% and 98% for Flow-MRD ≥ 0.1%) by 'different-from-normal' analysis. Median relapse kinetics were 0.78 log
Identifiants
pubmed: 38890448
doi: 10.1038/s41375-024-02300-z
pii: 10.1038/s41375-024-02300-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–91.
doi: 10.1182/blood-2017-09-801498
pubmed: 29330221
pmcid: 5865231
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Consensus Document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67.
doi: 10.1182/blood.2021013626
pubmed: 34724563
pmcid: 8718623
Ommen HB, Hokland P, Haferlach T, Abildgaard L, Alpermann T, Haferlach C, et al. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene. Br J Haematol. 2014;165:618–28.
doi: 10.1111/bjh.12792
pubmed: 24611505
Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Ostergaard M, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115:198–205.
doi: 10.1182/blood-2009-04-212530
pubmed: 19901261
Ommen HB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C, et al. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients. Eur J Haematol. 2015;95:436–41.
doi: 10.1111/ejh.12511
pubmed: 25605311
Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, et al. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. 2021;106:56–63.
doi: 10.3324/haematol.2019.235721
pubmed: 31896684
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022;140:1345–77.
doi: 10.1182/blood.2022016867
pubmed: 35797463
Hollein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv. 2018;2:3118–25.
doi: 10.1182/bloodadvances.2018023432
pubmed: 30455361
pmcid: 6258925
Schmalbrock LK, Dolnik A, Cocciardi S, Strang E, Theis F, Jahn N, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137:3093–104.
doi: 10.1182/blood.2020007626
pubmed: 33598693
pmcid: 8233666
Lawrence L. Making MRD Assessment Work for AML. 2023.
Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, et al. Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Adv. 2023;7:3666–76.
doi: 10.1182/bloodadvances.2022009493
pubmed: 37058448
pmcid: 10365943
Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2022;6:e676.
doi: 10.1097/HS9.0000000000000676
pubmed: 34964040
Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol. 2018;36:1486–97.
doi: 10.1200/JCO.2017.76.3425
pubmed: 29601212
pmcid: 5959196
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021;39:768–78.
doi: 10.1200/JCO.20.02308
pubmed: 33373276
Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, et al. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. Blood. 2023;142:1697–707.
doi: 10.1182/blood.2023020630
pubmed: 37595359
pmcid: 10667325
Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Computational Stat Data Anal. 2003;43:121–37.
doi: 10.1016/S0167-9473(02)00225-6
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N. Engl J Med. 2016;374:422–33.
doi: 10.1056/NEJMoa1507471
pubmed: 26789727
Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28:1212–23.
doi: 10.1038/s41591-022-01819-x
pubmed: 35618837
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N. Engl J Med. 2018;379:2330–41.
doi: 10.1056/NEJMoa1808777
pubmed: 30380364
pmcid: 6322675
Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, et al. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021;192:1054–63.
doi: 10.1111/bjh.17347
pubmed: 33618432
pmcid: 8944196
Jevremovic D, Nanaa A, Geyer SM, Timm M, Azouz H, Hengel C, et al. Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance. Am J Clin Pathol. 2022;158:530–6.
doi: 10.1093/ajcp/aqac083
pubmed: 35938646
pmcid: 9535519
Porwit A, Bene MC, Duetz C, Matarraz S, Oelschlaegel U, Westers TM, et al. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. Cytom B Clin Cytom. 2023;104:27–50.
doi: 10.1002/cyto.b.22108
Dillon LW, Ghannam J, Nosiri C, Gui G, Goswami M, Calvo KR, et al. Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis. Blood Cancer Discov. 2021;2:319–25.
doi: 10.1158/2643-3230.BCD-21-0046
pubmed: 34258102
pmcid: 8265308
Robinson TM, Bowman RL, Persaud S, Liu Y, Neigenfind R, Gao Q, et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023;9:eadg0488.
doi: 10.1126/sciadv.adg0488
pubmed: 37729414
pmcid: 10881057
Stasik S, Burkhard-Meier C, Kramer M, Middeke JM, Oelschlaegel U, Sockel K, et al. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. Blood Adv. 2022;6:3294–303.
doi: 10.1182/bloodadvances.2021006233
pubmed: 35320339
pmcid: 9198930
Dimitriou M, Mortera-Blanco T, Tobiasson M, Mazzi S, Lehander M, Hogstrand K, et al. Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation. Blood. 2024;143:953–66.